Thrombocytopenic Purpura Clinical Trial
Official title:
Initial Lymphocyte Counts Predictive Value in Immune Thrombocytopenic Purpura
Verified date | August 2017 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
- immune thrombocytopenic purpura is an acquired autoimmune disorder characterized by
increased platelet destruction and decreased platelet number (cooper N et al 2006)
- recent studies have demonstrated that the pathogenesis of ITP envolves multifactorial
autoimmune mechanisms of both humoral and cellular immunity and that acute and chronic
forms may represent two distinct immunopathological disorders ( cooper N et al 2006) (
Gern Sheimer T 2009 )
Status | Not yet recruiting |
Enrollment | 1 |
Est. completion date | January 2019 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Newly diagnosed cases of primary ITP , adults and children. Exclusion Criteria: - Cases of secondary ITP |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | lymphocyte count in immune thrombocytopenic purpura | intital lymphocyte counts predictive value in immune thrombocytopenic purpura by complete blood picture | 15 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00454857 -
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
|
N/A | |
Completed |
NCT01444417 -
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
|
Phase 3 | |
Completed |
NCT00508820 -
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
|
Phase 3 | |
Completed |
NCT00117143 -
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
|
Phase 1/Phase 2 | |
Completed |
NCT00415532 -
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
|
Phase 3 |